IL291287A - Litpol methods in cochlear jaundice - Google Patents

Litpol methods in cochlear jaundice

Info

Publication number
IL291287A
IL291287A IL291287A IL29128722A IL291287A IL 291287 A IL291287 A IL 291287A IL 291287 A IL291287 A IL 291287A IL 29128722 A IL29128722 A IL 29128722A IL 291287 A IL291287 A IL 291287A
Authority
IL
Israel
Prior art keywords
methods
alcoholic hepatitis
treating alcoholic
treating
hepatitis
Prior art date
Application number
IL291287A
Other languages
English (en)
Hebrew (he)
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Publication of IL291287A publication Critical patent/IL291287A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL291287A 2019-09-30 2022-03-10 Litpol methods in cochlear jaundice IL291287A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962908465P 2019-09-30 2019-09-30
US201962933206P 2019-11-08 2019-11-08
US202063060564P 2020-08-03 2020-08-03
US202063081208P 2020-09-21 2020-09-21
PCT/US2020/053315 WO2021067297A1 (en) 2019-09-30 2020-09-29 Treatment of alcoholic hepatitis

Publications (1)

Publication Number Publication Date
IL291287A true IL291287A (en) 2022-05-01

Family

ID=75336475

Family Applications (1)

Application Number Title Priority Date Filing Date
IL291287A IL291287A (en) 2019-09-30 2022-03-10 Litpol methods in cochlear jaundice

Country Status (13)

Country Link
US (2) US20220378802A1 (https=)
EP (1) EP4037650A4 (https=)
JP (1) JP7830313B2 (https=)
KR (1) KR20220075329A (https=)
CN (2) CN119868374A (https=)
AU (1) AU2020357818A1 (https=)
BR (1) BR112022005039A2 (https=)
CA (1) CA3155422A1 (https=)
IL (1) IL291287A (https=)
MX (1) MX2022003778A (https=)
PH (1) PH12022550698A1 (https=)
TW (1) TW202128184A (https=)
WO (1) WO2021067297A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
EP4359420A4 (en) * 2021-06-25 2025-07-16 Durect Corp 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE, PROCESSES FOR THEIR PREPARATION, AND THEIR USES
EP4611888A1 (en) * 2022-10-31 2025-09-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists
WO2025101669A1 (en) * 2023-11-07 2025-05-15 Durect Corporation Treatment of alcohol-associated hepatitis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
US20150072962A1 (en) * 2012-04-12 2015-03-12 Virgini Commonwealth University Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis
HRP20220112T1 (hr) * 2013-12-24 2022-04-15 Virginia Commonwealth University Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
EP3494125B1 (en) * 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
EP3493810A4 (en) * 2016-08-02 2020-04-08 Durect Corporation COMPOSITIONS WITH OXYGENOUS CHOLESTERINSULFATE AND AT LEAST POLYALKYLENE GLYCOL, CARBOXYMETHYLCELLULOSE OR POLYOXYL GLYCERIDE

Also Published As

Publication number Publication date
JP7830313B2 (ja) 2026-03-16
TW202128184A (zh) 2021-08-01
CA3155422A1 (en) 2021-04-08
BR112022005039A2 (pt) 2022-06-21
AU2020357818A1 (en) 2022-04-14
US20220378802A1 (en) 2022-12-01
CN119868374A (zh) 2025-04-25
PH12022550698A1 (en) 2023-04-03
JP2022549621A (ja) 2022-11-28
CN114555044B (zh) 2025-02-14
CN114555044A (zh) 2022-05-27
EP4037650A4 (en) 2023-10-18
EP4037650A1 (en) 2022-08-10
MX2022003778A (es) 2022-04-25
WO2021067297A1 (en) 2021-04-08
KR20220075329A (ko) 2022-06-08
US20260102410A1 (en) 2026-04-16

Similar Documents

Publication Publication Date Title
IL291287A (en) Litpol methods in cochlear jaundice
SG11202003488WA (en) Methods for treating hepatitis b infection
IL294214B2 (en) Cyclic compounds and methods for using them
EP3898628A4 (en) HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B VIRUS INFECTIONS
SG11202108029XA (en) Methods of treating multiple myeloma
IL285117A (en) Methods for characterizing properties related to condensation of compounds and their uses
IL284116A (en) Heteroaryldihydropyrimidine history and methods of treating hepatitis B infections
SG11202112232YA (en) Methods of treating neuropathy
GB2590601B (en) Method of mass spectrometry
ZA202202370B (en) Compositions and methods for treating viral infections
IL289032A (en) A method to reduce side effects of interferon
ZA202106233B (en) Method of improving sleep
IL290983A (en) Treatment methods
IL287250A (en) treatment method
IL288353A (en) Methods for treating cholangiocarcinoma
GB201918853D0 (en) Methods of treatment
GB201900250D0 (en) Method for virus propagation
IL288713A (en) Methods for treating viral infections
IL285822A (en) Methods for treating organic acidosis
IL282642A (en) Methods of using obeticholic acid
EP4045034A4 (en) METHODS OF TREATMENT OF HEPATITIS DELTA VIRUS INFECTIONS
HK40078571A (en) Treatment of alcoholic hepatitis
PL3810625T3 (pl) Sposoby i kompozycje do leczenia zakażenia wirusem zapalenia wątroby typu b
ZA202109005B (en) Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
HK40081168A (en) Methods of treating glioblastoma